Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
Sep 25th 2007Drug InformationClinical Trials
Biodel Inc. (Nasdaq: BIOD) announced that the Company has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe. Clinical sites have been initiated in Germany and patient treatment has begun. “We are expanding VIAject(TM)’s pivotal Phase III trials into Europe to support our planned European registration of VIAject(TM),” stated Dr. Solomon S. Steiner, Chairman and CEO of Biodel. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
